{"id":"W4411603000","doi":"10.1182/bloodadvances.2025015881","title":"Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Takeda Oncology; National Institutes of Health; MorphoSys; Health Resources and Services Administration; Syndax Pharmaceuticals; BeiGene; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; University of Pittsburgh; HistoGenetics; U.S. Department of Defense; Moonshot Research and Development Program; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Mallinckrodt Pharmaceuticals; Astellas Pharma US; U.S. Navy; Gateway for Cancer Research; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Amgen; Atara Biotherapeutics; National Cancer Institute; Servier; Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Internal medicine; Gastroenterology; Pediatrics; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005042543,0.0006179965,0.00129323,0.001954517,0.0002697547,0.001556558,0.0008277186,0.0006780047,0.002505398],"category_scores_gemma":[0.01008308,0.0004090257,0.004007353,0.003444652,0.0003169928,0.001222859,0.0009864146,0.0008391656,0.0005630017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006519936,"about_ca_system_score_gemma":0.0004894618,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001965623,"about_ca_topic_score_gemma":0.003156061,"domain_scores_codex":[0.993608,0.002662919,0.001143172,0.00125738,0.0008098689,0.0005187648],"domain_scores_gemma":[0.990694,0.002236749,0.004093885,0.002018822,0.0005661017,0.0003905347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00740328,0.00009546695,0.9730311,0.0003796137,0.01044705,0.0002075536,0.0001275991,0.0006842437,0.000427273,0.0001262141,0.002362221,0.004708412],"study_design_scores_gemma":[0.0007890456,0.0007057744,0.986963,0.0001077398,0.004902042,0.0005864033,0.000474371,0.001731816,0.0003136148,0.0002010654,0.00316463,0.00006045675],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736087,0.003823625,0.0006020128,0.0001937676,0.00004917022,0.0001182612,0.02030227,0.00003355476,0.001268549],"genre_scores_gemma":[0.9866476,0.0002860953,0.0001922985,0.0000786987,0.00003933076,0.000112667,0.01241946,0.00002622116,0.0001977482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005042543,"threshold_uncertainty_score":0.02666783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07493340698245726,"score_gpt":0.4053863752245954,"score_spread":0.3304529682421382,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}